Clinical momentum Peptomyc is a clinical-stage biotech focused on MYC inhibitors with lead candidate OMO-103 and a Phase 2 trial in osteosarcoma, indicating ongoing development and a need for strategic partnerships, CRO support, and potential licensing opportunities.

Funding activity Recent equity financing of €5 million and a $46K grants plan, plus a total funding of $33M, suggest active fundraising and grant opportunities; potential for co-investment, strategic collaborations, and milestone-driven partnerships with investors and grant sponsors.

Executive hiring Key leadership appointments and near-term CEO onboarding signal strategic shifts and growth focus; leverage to engage C-suite alignment discussions, potential advisory roles, and collaboration on clinical development strategy and partnerships.

Clinical partnerships As a spin-off from VHIO and ICREA with a direct MYC inhibitor in clinical validation, there is strong appeal for research collaborations, translational studies, patient recruitment networks, and joint ventures with academic centers and biotech peers.

Market positioning First-in-class approach targeting MYC with a mini-protein therapeutic niche and pediatric-adult osteosarcoma focus positions Peptomyc for niche, high-value deals; explore opportunities for licensing, milestone-based collaborations, and specialized contract research services.